| Title |
Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, August 2016
|
| DOI | 10.1007/s00259-016-3490-6 |
| Pubmed ID | |
| Authors |
Johannes Schwenck, Hansjoerg Rempp, Gerald Reischl, Stephan Kruck, Arnulf Stenzl, Konstantin Nikolaou, Christina Pfannenberg, Christian la Fougère |
| Abstract |
Prostate-specific membrane antigen (PSMA) is expressed ubiquitously on the membrane of most prostate tumors and its metastasis. While PET/CT using (11)C-choline was considered as the gold standard in the staging of prostate cancer, PET with radiolabelled PSMA ligands was introduced into the clinic in recent years. Our aim was to compare the PSMA ligand (68)Ga-PSMA-11 with (11)C-choline in patients with primary and recurrent prostate cancer. 123 patients underwent a whole-body PET/CT examination using (68)Ga-PSMA-11 and (11)C-choline. Suspicious lesions were evaluated visually and semiquantitatively (SUVavg). Out of these, 103 suffered from a confirmed biochemical relapse after prostatectomy and/or radiotherapy (mean PSA level of 4.5 ng/ml), while 20 patients underwent primary staging. In 67 patients with biochemical relapse, we detected 458 lymph nodes suspicious for metastasis. PET using (68)Ga-PSMA-11 showed a significantly higher uptake and detection rate than (11)C-choline PET. Also (68)Ga-PSMA-11 PET identified significantly more patients with suspicious lymph nodes as well as affected lymph nodes regions especially at low PSA levels. Bone lesions suspicious for prostate cancer metastasis were revealed in 36 patients' biochemical relapse. Significantly more bone lesions were detected by (68)Ga-PSMA-11, but only 3 patients had only PSMA-positive bone lesions. Nevertheless, we detected also 29 suspicious lymph nodes and 8 bone lesions, which were only positive as per (11)C-choline PET. These findings led to crucial differences in the TNM classification and the identification of oligometastatic patients. In the patients who underwent initial staging, all primary tumors showed uptake of both tracers. Although significantly more suspicious lymph nodes and bone lesions were identified, only 2 patients presented with bone lesions only detected by (68)Ga-PSMA-11 PET. Thus, PET using (68)Ga-PSMA-11 showed a higher detection rate than (11)C-choline PET for lymph nodes as well as bone lesions. However, we found lymph nodes and bone lesions which were not concordant applying both tracers. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 146 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 146 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 14% |
| Student > Ph. D. Student | 17 | 12% |
| Student > Bachelor | 13 | 9% |
| Other | 13 | 9% |
| Student > Master | 13 | 9% |
| Other | 27 | 18% |
| Unknown | 43 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 56 | 38% |
| Chemistry | 9 | 6% |
| Engineering | 6 | 4% |
| Nursing and Health Professions | 5 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
| Other | 17 | 12% |
| Unknown | 48 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2023.
All research outputs
#7,833,677
of 24,293,076 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#1,012
of 3,388 outputs
Outputs of similar age
#118,178
of 347,444 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#14
of 44 outputs
Altmetric has tracked 24,293,076 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,388 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one has gotten more attention than average, scoring higher than 69% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 347,444 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.